Bispecific Antibodies Webinar

SELEXIS WEBINAR:
Next-generation cell line development platform for advanced bispecific antibodies expression


Selexis Bispecific Antibody

A bispecific monoclonal antibody (bsAbs), or multispecific antibody, can simultaneously bind to two or more different types of antigen. Bispecifics can be manufactured in several structural formats, and current applications have been explored for cancer immunotherapy and drug delivery. The promise of bispecifics comes from their ability to behave like a cellular therapy, even though they are an “off-the-shelf” product.  An “off-the-shelf” therapy, rather than one that needs to be manufactured individually for each patient (such as chimeric antigen receptor T (CAR-T) cell therapies), can be a life-saving proposition for patients facing difficult-to-treat and rapidly progressing disease, such as many cancers.

In our webinar “Next-generation cell line development platform for advanced bispecific antibodies expression,” we will address the key challenges of expressing bispecifics in Chinese hamster ovary (CHO) cells.

EU SESSION

Tuesday, June 23
Geneva 1:00 PM – 1:40 PM CEST
30 minutes presentation
10 minutes Q/A

https://attendee.gotowebinar.com/register/9211016132681398031

US SESSION

Tuesday, June 23
San Francisco 9:00 AM – 9:40 AM PT
Boston 12:00 PM – 12:40 PM ET
Geneva 6:00 PM – 6:40 PM CEST
30 minutes presentation
10 minutes Q/A

https://attendee.gotowebinar.com/register/4484803883594710799

YOU WILL LEARN

Diversity of recombinant scaffolds expressed with Selexis’ SUREtechnology Platform™

Modulation of bispecific assembly and expression at the molecular scale using SUREtech™ vectors

Small scale quality-oriented screening of bispecifics to accelerate cell line development timelines

Plug-and-play transfer of bispecific-expressing cell lines to CMO/CDMOs

WHO SHOULD ATTEND

Scientist developing bispecific therapeutics

Cell line development scientists and researchers

Biologics development scientists

WEBINAR ABSTRACT

We will present a breakthrough cell line development platform using a single-cell system to express any bispecific antibody (bsAb) format. Separate vectors, each harboring a different polypeptide chain from a bsAb, are adjusted to favor bias towards heterodimer production. Early screening by microcapillary electrophoresis allows for rapid determination of different hetero- vs homodimeric populations and identification of clones with the desired phenotype. Scalability and stability issues will be discussed.  Case studies will be presented.

ABOUT THE SPEAKER

Séverine Fagète
VP, Cell Line Development Services
Séverine joined Selexis in December 2015 to lead the Cell Line Development, the Bioprocess and the Analytics Departments. In her role, she ensures the continuous generation of high-performance stable cell lines, including recombinant protein characterization. Séverine also works on providing scale-down bioreactor data using Ambr® 15 to facilitate the transfer to CMOs. Séverine earned her PhD in protein engineering from a private company, Novimmune, where she focused on the generation of broad-spectrum chemokine inhibitors by using directed mutagenesis, phage display isolation, functional characterization and epitope mapping. She subsequently held a postdoctoral position at the University of Geneva (CH, Prof. Hartley’s group) where she designed a novel phage display platform for accelerating bispecific antibody development.
Severine Fagete, VP Cell Line Development Services

EU SESSION

Tuesday, June 23
Geneva 1:00 – 1:40 PM CEST
30 minutes presentation
10 minutes Q/A

https://attendee.gotowebinar.com/register/9211016132681398031

US SESSION

Tuesday, June 23
San Francisco 9:00 AM PT – 9:40 AM PT
Boston 12:00 PM ET – 12:40 PM ET
Geneva 6:00 PM CEST – 6:40 PM CEST
30 minutes presentation
10 minutes Q/A

https://attendee.gotowebinar.com/register/4484803883594710799


Cell Line Development Partner of Choice

Selexis SA, A JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines.

Selexis SUREtechnology Platform

Our global partners are utilizing Selexis gene technologies to advance more than 130 drug products in clinical development and the manufacture of seven commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks.